Business
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE)
About this update from Caredx, Inc.
[{"type":"text","content":"Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes\nSOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Giménez as the winner of the CareDx sponsored ISHLT Innovation Challenge Award. Along with her collaborators at the Hospital Vall Hebrón in Barcelona, Spain, Dr. Sáez-Giménez will use AlloSeq™ cfDNA (cell-free DNA) to monitor the treatment of chronic lung allograft dysfunction, a condition associated with high mortality and morbidity in lung transplantation.1,2 Lung transplant patients have one of the lowest median survivals of any solid organ transplant recipient, with a five-year survival rate of approximately 53%3, and chronic lung allograft dysfunction is one of the leading causes of mortality.1,2 CareDx has made AlloSeq cfDNA available to laboratories outside the U.S. to enable testing analogous to AlloSure® Lung, which can offer early warnings to physicians of organ injuries, including rejection which can help inform timely interventions.2 AlloSeq cfDNA is CE marked in Europe for surveillance of dd-cfDNA in solid organ transplantation. \"As a leader committed to advancing the field of transplantation, CareDx is proud to sponsor the ISHLT Innovation Challenge Award. This award will help advance the important research that Dr. Sáez-Giménez is undertaking to address one of the most pressing issues facing lung transplant patients, the development of irreversible chronic lung allograft dysfunction and one of the leading causes of mortality,\" said Reg Seeto, CEO and President of CareDx. The ISHLT Innovation Challenge Award recognized research proposals that evaluated the clinical utility of using non-invasive solutions to improve outcomes in heart and lung transplant patients - specifically, research evaluating the clinical utility of combining donor-derived cell-free DNA (dd-cfDNA) and gene-expression profiling (GEP) in heart transplantation, or dd-cfDNA in lung transplantation. \"When the ISHLT panel of judges (comprised of ISHLT Grants ...